Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | NQO2 | P16083 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064188 | 0.91 | MTNR1A (0.83) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL3065294 | 0.91 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL6810063 | 0.83 | MTNR1A (0.79) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL6810066 | 0.83 | MTNR1A (0.79) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL1566122 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29237 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL338730 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL1566207 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306167-A1 | Pharmaceutical Compositions for Intranasal Administration Comprising a Melatonin Receptor Agonist, Uses Thereof | INTRANASAL THERAPEUTICS, INC. | 2009-12-10 | — | — | US | claimed |
| WO-2007109141-A2 | PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION COMPRISING A MELATONIN RECEPTOR AGONIST, USES THEREOF | INTRANASAL THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8183285-B2 | Therapeutic agent for irritable bowel syndrome and methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2248808-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090306167-A1 | Pharmaceutical Compositions for Intranasal Administration Comprising a Melatonin Receptor Agonist, Uses Thereof | INTRANASAL THERAPEUTICS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-1214944-B1 | Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1550655-A1 | Bicyclic intermediates | Takeda Pharmaceutical Company Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1214944-A1 | PERCUTANEOUS ABSORPTION AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-19 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| CN-1212691-A | Tricyclic compounds, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-03-31 | — | — | CN | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885ABCB11 148/4885 |
| US-20090306167-A1 | Pharmaceutical Compositions for Intranasal Administration Comprising a Melatonin Receptor Agonist, Uses Thereof | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885ABCB11 2508/4885 |
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | HRH4, HRH2, HRH3 | MTNR1A 21/4885MTNR1B 34/4885ABCB11 1325/4885 |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | HRH4, HRH2, HRH3 | MTNR1A 21/4885MTNR1B 34/4885ABCB11 1325/4885 |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1A 99/4885MTNR1B 56/4885ABCB11 1696/4885 |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1A 99/4885MTNR1B 56/4885ABCB11 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.